A review of PARP inhibitors: from bench to bedside.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of Oncology

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdq322PMID 20643861
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer.

  2016cited by this paper
• Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.

  2010cited by this paper
• A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.

  2009cited by this paper
• PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.

  2009cited by this paper
• Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.

  2009cited by this paper
• Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

  2009cited by this paper
• Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).

  2009cited by this paper
• Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

  2009cited by this paper
• Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

  2009cited by this paper
• In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

  2009cited by this paper
• A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

  2009cited by this paper
• Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

  2009cited by this paper
• Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.

  2009cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

  2008cited by this paper
• First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

  2008cited by this paper
• A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors

  2008cited by this paper
• AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

  2008cited by this paper
• Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2008cited by this paper
• Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

  2008cited by this paper
• 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

  2008cited by this paper
• Targeted therapy for cancer using PARP inhibitors.

  2008cited by this paper
• "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

  2008cited by this paper
• The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

  2008cited by this paper
• PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.

  2008cited by this paper
• PARP inhibitor development for systemic cancer targeting.

  2007cited by this paper
• The New Zealand Asthma and Allergy Cohort Study (NZA2CS): Assembly, Demographics and Investigations

  2007cited by this paper
• Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice

  2007cited by this paper
• Mutator pathways unleashed by epigenetic silencing in human cancer.

  2007cited by this paper
• First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

  2007cited by this paper
• First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

  2006cited by this paper
• Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis

  2006cited by this paper
• The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours.

  2006cited by this paper
• In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs)

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

  2005cited by this paper
• Treating cancer by targeting a weakness.

  2005cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors

  2005cited by this paper
• PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.

  2004cited by this paper
• Fas induces apoptosis in human coronary artery endothelial cells in vitro

  2004cited by this paper
• Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

  2004cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• The PARP superfamily

  2004cited by this paper
• The role of BRCA1 in the cellular response to chemotherapy.

  2004cited by this paper
• Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

  2004cited by this paper
• Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery

  2003cited by this paper
• Breast and ovarian cancer.

  2003cited by this paper
• Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

  2003cited by this paper
• Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse

  2003cited by this paper
• A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.

  2003cited by this paper
• Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

  2003cited by this paper
• Poly(ADP-ribosyl)ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein.

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

  2002cited by this paper
• The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

  2002cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences

  2001cited by this paper
• Profiling familial breast cancer

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Loss of poly(ADP‐ribose) polymerase‐1 causes increased tumour latency in p53‐deficient mice

  2001cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers

  2000cited by this paper
• Reduction of BRCA1 expression in sporadic ovarian cancer.

  2000cited by this paper
• Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

  1999cited by this paper
• Involvement of Brca2 in DNA repair.

  1998cited by this paper
• Integrating genetic approaches into the discovery of anticancer drugs.

  1997cited by this paper
• Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.

  1997cited by this paper
• Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks.

  1995cited by this paper
• Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

  1995cited by this paper
• Overproduction of the poly(ADP‐ribose) polymerase DNA‐binding domain blocks alkylation‐induced DNA repair synthesis in mammalian cells.

  1993cited by this paper
• Instability and decay of the primary structure of DNA

  1993cited by this paper
• Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo.

  1989cited by this paper
• Comparison between the DNA precipitation and alkali unwinding assays for detecting DNA strand breaks and cross-links.

  1988cited by this paper
• Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl nicotinamide.

  1971cited by this paper
• Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme.

  1963cited by this paper
• Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.

  1946cited by this paper
• Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura.

  1946cited by this paper

• Discovery of novel thiosemicarbazone dimers as effective inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) for use in cancer therapy.

  2025cites this paper
• PARP inhibitors as radiosensitizers: a comprehensive review of preclinical evidence and clinical applications

  2025cites this paper
• Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

  2025cites this paper
• Understanding DNA and PARP in Cancer: Tackling Inhibitor Resistance.

  2025cites this paper
• The Prognostic Value of the XPC rs2228001 Single Nucleotide Polymorphism in Cholangiocarcinoma

  2025cites this paper
• Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application

  2024cites this paper
• Synthesis and bioevaluation of a new 68Ga-labelled niraparib derivative that targets PARP-1 for tumour imaging.

  2024cites this paper
• Design of Selective PARP-1 Inhibitors and Antitumor Studies.

  2024cites this paper
• FLIP(C1orf112)-FIGNL1 complex regulates RAD51 chromatin association to promote viability after replication stress

  2024cites this paper
• PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for

  2024cites this paper
• PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

  2024influential citation
• DNA-PKcs mediated transcriptional regulation of TOP2β drives chemoresistance in acute myeloid leukemia.

  2024cites this paper
• Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.

  2024cites this paper
• Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer

  2024cites this paper
• Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader

  2024cites this paper
• Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis.

  2024cites this paper
• Veliparib: Analytical Tools and Process Design Strategies for the Control of Mutagenic Impurities and Other Drug Substance Critical Quality Attributes

  2024cites this paper
• The Integration of Radiotherapy with Systemic Therapy in Advanced Triple-Negative Breast Cancer.

  2024cites this paper
• A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA Damage-Activated cGAS-STING Pathway.

  2024cites this paper
• Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies.

  2024cites this paper
• RADIF(C1orf112)-FIGNL1 Complex Regulates RAD51 Chromatin Association to Promote Viability After Replication Stress

  2023cites this paper
• A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins

  2023cites this paper
• Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway

  2023cites this paper
• Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer

  2023cites this paper
• Advances in Development of Selective Antitumor Inhibitors That Target PARP-1.

  2023cites this paper
• YCH1899, a Highly Effective Phthalazin-1(2H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors.

  2023cites this paper
• Present and future of HER2 positive and triple negative breast cancer

  2023cites this paper
• A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).

  2023cites this paper
• PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities

  2023cites this paper
• Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer

  2023cites this paper
• Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer

  2023cites this paper
• Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

  2022cites this paper
• A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.

  2022cites this paper
• VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system

  2022cites this paper
• A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers

  2022cites this paper
• Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity

  2022cites this paper
• Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses

  2022cites this paper
• [Practical management of PARP inhibitors: A French DELPHI consensus].

  2022cites this paper
• Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.

  2022cites this paper
• Prevention and treatment of the side effects of poly-ADP-ribose polymerase-1 inhibitors (iPARP) in breast and ovarian cancer

  2021cites this paper
• Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer

  2021cites this paper
• PARP inhibitors in various cancers

  2021cites this paper
• Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.

  2021cites this paper
• PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: implications for CNS disease therapeutics.

  2021cites this paper
• Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.

  2021cites this paper
• DNA Damage Repair Proteins (PARP1, XRCC1 and POLβ) have Unfavorable Potential Prognostic Role in Primary Ovarian Cancer

  2021cites this paper
• VRK1 is required in VRK2-methylated cancers of the nervous system

  2021cites this paper
• PARP Inhibitors and Haematological Malignancies—Friend or Foe?

  2021cites this paper
• Extra Virgin Olive Oil consumption from Mild Cognitive Impairment patients attenuates oxidative and nitrative stress reflecting on the reduction of the PARP levels and DNA damage.

  2021cites this paper
• Impairment of neuronal mitochondrial function by l-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage

  2021cites this paper
• QSAR Study of PARP Inhibitors by GA-MLR, GA-SVM and GA-ANN Approaches

  2020cites this paper
• α‐Aminophosphonates as Potential PARP1 Inhibitors

  2020cites this paper
• Probing the Conformational Changes Associated with DNA-Binding to PARP1.

  2020cites this paper
• Novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor DDHCB inhibits proliferation of BRCA mutant breast cancer cell in vitro and in vivo through a synthetic lethal mechanism.

  2020cites this paper
• The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

  2020cites this paper
• Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment

  2020cites this paper
• Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.

  2020cites this paper
• QSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction

  2020cites this paper
• PARP inhibition synergizes with melphalan but does not reverse resistance completely.

  2020cites this paper
• PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO).

  2020cites this paper
• OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis

  2020cites this paper
• The Treatment of Clear Cell Ovarian Cancer with the Poly(ADP- Ribose) Polymerase (PARP1) Inhibitors (AG14361,Veliparib,Olaparib) as Chemosensitizers.

  2020cites this paper
• Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.

  2020cites this paper
• Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy.

  2020cites this paper
• Flavonoids from Rosa roxburghii Tratt prevent reactive oxygen species-mediated DNA damage in thymus cells both combined with and without PARP-1 expression after exposure to radiation in vivo

  2020cites this paper
• Origin of Genome Instability and Determinants of Mutational Landscape in Cancer Cells

  2020cites this paper
• Predicting PARP inhibitory activity – A novel quantum mechanical based model

  2020influential citation
• Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas

  2020cites this paper
• Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study

  2020cites this paper
• BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.

  2020cites this paper
• Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

  2020cites this paper
• The Treatment of Clear Cell Ovarian Cancer with the Poly(ADP- Ribose) Polymerase (PARP1) Inhibitors (AG14361,Veliparib,Olaparib) as Chemosensitizers

  2020cites this paper
• The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.

  2020cites this paper
• Differential Expression Profile of NLRs and AIM2 in Glioma and Implications for NLRP12 in Glioblastoma

  2019cites this paper
• Protein Interaction Domains and post-translational modifications: structural features and drug discovery applications.

  2019cites this paper
• Overcoming Resistance to PARP Inhibition

  2019cites this paper
• A MACHINE LEARNING APPROACH TO PATTERN DISCOVERY IN ONCOGENOMICS

  2019cites this paper
• The Role of Poly(ADP-Ribose) Polymerase-1 in Cutaneous Wound Healing

  2019cites this paper
• Triple negative breast cancer: A thorough review of biomarkers.

  2019cites this paper
• Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.

  2019cites this paper
• PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade

  2019cites this paper
• PARP Inhibition in Cancer: An Update on Clinical Development

  2019cites this paper
• Precision medicine in gastric cancer

  2019cites this paper
• Identification and quantification of DNA repair protein poly(ADP ribose) polymerase 1 (PARP1) in human tissues and cultured cells by liquid chromatography/isotope-dilution tandem mass spectrometry.

  2019cites this paper
• PARP-14 Promotes Survival of Mammalian α but Not β Pancreatic Cells Following Cytokine Treatment

  2019cites this paper
• Die personalisierte Therapie beim Ovarialkarzinom

  2018cites this paper
• The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer

  2018cites this paper
• Biomarkers for Homologous Recombination Deficiency in Cancer

  2018cites this paper
• The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer

  2018cites this paper
• Targeting vulnerabilities through inhibiting the valosin-containing protein (VCP/p97) in ovarian cancer

  2018cites this paper
• Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.

  2018cites this paper
• Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?

  2018cites this paper
• Poly(ADP‐Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer‐Initiating Cells to Chemotherapy

  2018cites this paper
• Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.

  2018cites this paper
• High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients

  2018cites this paper
• Die personalisierte Therapie beim Ovarialkarzinom

  2018influential citation
• A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

  2017cites this paper
• BRCA-Diagnostik an Ovarialkarzinomen

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Tumor cells can ’ t stand the heat Oei

  2017cites this paper
• Reverse the Resistance to PARP Inhibitors

  2017influential citation